Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoADAURA: neoadjuvant osimertinib with or without chemotherapy versus chemotherapy alone in EGFR-mutant resectable non-small cell lung cancer
2020-000058-89Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of osimertinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by AstraZeneca. Primary endpoint: Major Pathological Response. Started Apr 2020; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-000058-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000058-89.